Indications:

• Major depressive disorder (MDD).
• Obsessive-compulsive disorder (OCD).
• Generalised anxiety disorder (GAD).
• Social anxiety disorder (social phobia, SAD).
• Panic disorder (PD) with or without agoraphobia.

 

Also OFF-LABEL:

• Premature ejaculation.
• Bulimia.

 

Administration and dosage: According to a doctor prescription.

 

Indication	Prescription	Effect	Duration
MDD	½ tab (10mg/day). Depending on individual response, the dose may be increased to a 1 tab/day (20mg/day)	2-4 weeks	At least 6 months after the symptoms resolve
OCD	½ tab (10mg/day). Depending on individual response, the dose may be increased to a 1 tab/day (20mg/day)	–	Several months
GAD	½ tab (10mg/day). Depending on individual response, the dose may be increased to a 1 tab/day (20mg/day)	–	3 months. Another 6 months to prevent relapse, depending on individual response
SAD	½ tab (10mg/day) for 2-4 weeks. The dose may subsequently, depending on individual patient response, be decreased to 5mg/day (¼ tab) or increased to a maximum of 20mg/day (1 tab)	2-4 weeks	3 months. Another 6 months to prevent relapse, depending on individual response
ПР	¼ tab (5mg/day) for 1 week, then ½ tab (10mg/day). Depending on individual response, the dose may be increased to a 1 tab/day (20mg/day)	3 months	Several months

 

Contraindications:

• Hypersensitivity to the active substance or to any of the excipients.
• Age under 18 years.
• Known QT interval prolongation or congenital long QT syndrome.
• Together with medicinal products that are known to prolong the QT interval.
• Concomitant treatment with non-selective, monoamine oxidase inhibitors (MAO-inhibitors) due to the risk of serotonine syndrome.

 

Packing: 14 oval shaped, white to off white, f/c tablets with break line on one side in a blister. 2 blisters (28 f/c tablets) in a cardboard box along with a leaflet.

Produced by “Delorbis”, Cyprus

See also: http://www.delorbispharma.eu